Biotricity has received FDA 510 (k) approval for heart control devices –

A VPN is an essential component of IT security, whether you’re just starting a business or are already up and running. Most business interactions and transactions happen online and VPN


Biotricity received FDA 510 (k) approval for cardiac monitoring devices

What you should know:

Biotricity, Inc. (NASDAQ: BTCY), a medical diagnostics and consumer healthcare technology company, announced today that it has received 510 (k) approval from the U.S. Food and Drug Administration (FDA) for its heart monitoring device. Biotres, a three-lead device for ECG and arrhythmia monitoring for lower-risk patients.

– Most remote heart rate monitors are passive (do not record ECG and other cardiac data in real time) and do not have cross-compatibility with other platforms / devices. In contrast, Biotricity’s expanding set of cardiac monitoring technologies is a turnkey solution that offers the advanced and continuous type of monitoring that allows cardiologists to see warning signs before and act proactively and integrates seamlessly. to existing systems. Biotres is not only expanding our product portfolio, but also opening a new market and increasing the total addressable Biotricity market from $ 1 billion to $ 5.7 billion and will be widely available for sale from on April 1, 2022.

– The Biotres not only expands our product portfolio, but also opens a new market and increases Biotricity’s total addressable market from $ 1 billion to $5.7 billion and will be widely available for sale from April 1, 2022.



Source link

TheHealthReporter

TheHealthReporter

Recent Posts

Enhance your Cisco HIMSS24 experience
The Cisco Customer Experience Healthcare Practice helps customers leverage the use of Cisco technology...
Read More
HIMSS 2024 Find out before you go
The future of healthcare is coming into focus! Now more than ever, we believe that technology is a critical...
Read More
How GLP-1 Drug Success Is Transforming Healthcare Revenue: Is Your Organization Ready?
The huge revenue opportunity arising from the recent success of GLP-1 drugs is not just for pharmaceutical...
Read More

Related Posts